Healthcare Private Placement and M&A Transactions Review

Rasolute Therapeutics: The company raised $450 million of Series B venture funding in a deal led by softBank and Arc Ventures on June 1, 2026. The company is a developer of precision oncology therapeutics designed to treat RAS-driven cancers.

NewLimit: The company raised $435 million of Series C venture funding in a deal led by Founders Fund on June 2, 2026, putting the company’s pre-money valuation at $2.67 billion. The company is a developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells.

Chai Discovery: The company is in the process of raising $400 million of venture funding as of June 4, 2026, putting the company’s pre-money valuation at $3 billion. The company is a developer of an AI platform for molecular structure prediction and molecular interaction modeling in drug discovery.

Collate: The company raised $95 million of Series A venture funding in a deal led by Redpoint Ventures, First Round Capital, CRV, Y Combinator and Conviction Partners on June 3, 2026, putting the company’s pre-money valuation at $905 million. The company is a developer of an AI-based documentation platform designed to support life sciences product development workflows.

Contraline: The company raised $92.5 million in Series B venture funding in a deal led by BVF Partners and RA Capital Management on June 2, 2026, putting the company’s pre-money valuation at $105 million. The company is a developer of a male contraceptive product intended to provide non-surgical and reversible birth control procedures.

CereVasc: The company raised $85 million of Series C venture funding in a deal led by Piper Sandler on June 4, 2026. The company is an operator of a medical device company developing treatments for patients with neurological diseases.

BioIntelliSense: The company raised $58 million of Series C venture funding from undisclosed investors on June 1, 2026. The company is a developer of a clinical intelligence and medical-grade wearable technology company that specializes in continuous, remote patient monitoring.

Semble: The company raised EUR 30 million of venture funding in a deal led by Revaia and Andreessen Horowitz on June 4, 2026. The company is a developer of a cloud-based clinical system for medical practice management, patient records, and administration.

Subtle Medical: On June 2, 2026, the company secured $33 million in venture funding in a round led by Morgan Stanley Expansion Capital, with participation from Samsung Venture Investment, The company is an operator of a healthcare technology platform intended to use deep learning to increase the quality and efficiency of medical imaging.

Nia Therapeutics: The company raised $23.5 million of venture funding from Ben Franklin Technology Partners of Southeastern Pennsylvania, Paeonia Group and and other undisclosed investors on June 3, 2026. The company is a developer of a neurostimulation device designed to treat memory loss associated with brain injuries and neurodegenerative conditions.

POP Biotechnologies: The company closed on $9.7 million of an undisclosed targeted amount of venture funding from Coalition for Epidemic Preparedness Innovations on June 3, 2026. The company is a developer of targeted therapies designed to treat cancer and other life-threatening diseases.

Scispot: The company raised $8 million of venture funding in a deal led by Avenue Growth Partners on June 4, 2026. The company is a developer of a lab operations platform that unifies workflows, data, and automation across research labs.

Kalogon: The company raised $5.8 million of venture funding in a deal led by Enable Ventures on June 4, 2026. The company is a developer of a smart medical cushion technology designed to prevent pressure sores and eliminate discomfort for wheelchair users.

Channel Robotics: The company raised $4.7 million of venture funding from Old Line Capital Partners and other undisclosed investors on June 2, 2026. The company is a developer of miniaturized surgical robotic systems designed for endoscopic procedures.

Galaxy Diagnostics: The company raised $3 million of Series A venture funding from undisclosed investors on June 3, 2026, putting the company’s pre-money valuation at $11.2 million. The company is an operator of an advanced diagnostic testing platform intended to improve the detection of stealth pathogens.

MeAgain: The company raised an undisclosed amount of venture funding from Freestyle Capital in June 2026. The company is a developer of a GLP-1 health application for personalized plans and advanced progress tracking.

Serova: The company raised an undisclosed amount of venture funding from Freestyle Capital in June 2026. The company is an operator of a personalized cancer vaccine platform designed to create patient-specific cancer immunotherapies based on evolving tumor biology.

Verisian: The company raised an undisclosed amount of venture funding from Recode Health Ventures in June 2026. The company is a developer of a clinical research analytics platforms for improving transparency and decision-making in trial evaluation.

Edgewise Therapeutics / Servier: The Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics reached a definitive agreement to be acquired by Servier, a subsidiary of Arts Et Technique Du Progres, for $2.7 billion on June 1, 2026. The company is a provider of muscular dystrophy therapy services based in Boulder, Colorado.

Swixx Biopharma / Bain Capital Life Sciences: The company was acquired by SK Capital Partners and Bain Capital Life Sciences through a EUR 1.5 billion LBO on June 1, 2026. The company is a provider of outsourced commercial and distribution services for biopharma, OTC, and medical device companies across Central and Eastern Europe.

Neurona Therapeutics / UCB: The company was acquired by UCB, a subsidiary of Digital Care Transformation, for $1.2 billion on June 2, 2026. The company is a developer of regenerative cell therapies designed for the treatment of chronic neurological disorders.

Obagi Cosmeceuticals / Bridgepoint Group: The company, a subsidiary of Waldencast entered into a definitive agreement to be acquired by Bridgepoint Group through a $460 million LBO on June 1, 2026. The company is a manufacturer and retailer of skin care products for aging, pigmentation, acne, and other dermatologic concerns.

Vitalware / Med-Metrix: The company, a subsidiary of Health Catalyst entered into a definitive agreement to be acquired by Med-Metrix, via its financial sponsors Harvest Partners and A&M Capital through a $147 million LBO on June 4, 2026. The company is a developer of a cloud-based SaaS platform designed to document, code, and audit healthcare records.

AYUMI Pharmaceutical / GNI Group: The company reached a definitive agreement to be acquired by GNI Group for an estimated JPY 44.8 billion on June 5, 2026. The company is a manufacturer of specialty pharmaceuticals based in Tokyo, Japan.

Vesica Health / Photocure: The company was acquired by Photocure for $30.5 million on June 4, 2026. The company is a developer of diagnostic technology designed for clinical evaluation of patients with hematuria and early detection of bladder cancer.

Contextflow / 4DMedical: The company reached a definitive agreement to be acquired by 4DMedical for $18.6 million on June 1, 2026. The company is a developer of AI-based radiology decision support software for image analysis in respiratory disease.

Aster / Elation Health: The company was acquired by Elation Health for an undisclosed amount on June 2, 2026. The company is an operator a virtual women’s health care platform intended for remote pregnancy and postnatal care.

Avenzo Therapeutics / Rallybio: The company reached a definitive agreement to Rallybio through a reverse merger, resulting in the combined entity trading on the Nasdaq under the ticker symbol AVZO on June 1, 2026. The company is an operator of a clinical-stage oncology platform developing novel treatments for underserved cancers.

Azena Medical / Ultradent Products: The company was acquired by Ultradent Products for an undisclosed amount on June 5, 2026. The company is an operator of a medical device design firm specializing in semiconductor laser technology for medical and dental markets.

Cellmyx / Micro Identification Technologies: The company was acquired by Micro Identification Technologies for an undisclosed amount on June 5, 2026. The company is a designer and manufacturer of proprietary medical technology products and medical devices designed for the harvesting, processing, and deployment of autologous soft tissue.

Lineus Medical / KMF Investments: The company was acquired by KMF Investments for an undisclosed amount on June 1, 2026. The company is a developer of a break-away intravenous therapy device compatible with standard medical tubing.

Loyal / Clarify: The company was acquired by Clarify for an undisclosed amount on June 4, 2026. The company is a developer of patient data intelligence software for digital patient engagement.

Medoucine / Cegedim Santé: The company was acquired by Cegedim Santé, a subsidiary of Cegedim for an undisclosed amount on June 1, 2026. The company is a developer of a booking platform connecting patients with alternative medicine practitioners.

Nutrisense / DexCom: The company was acquired by DexCom for an undisclosed amount on June 4, 2026. The company is an operator of a health-tracking platform that provides personalized nutrition and metabolic health insights.

Pantherna Therapeutics / T-Curx: The company was acquired by T-Curx for an undisclosed amount on June 1, 2026. The company is an operator of a biopharmaceutical platform intended to develop therapeutics for vascular diseases.

Rapidwerks / TEAM Technologies: The company was acquired by TEAM Technologies, via its financial sponsors Ares Management and Arlington Capital Partners, through an LBO on June 4, 2026 for an undisclosed amount. The company is a manufacturer of precision micro-molded components intended for the medical device and pharmaceutical sectors.

Sunrise Rx / AvevoRx: The company was acquired by AvevoRx for an undisclosed amount on June 4, 2026. The company is a provider of specialty pharmacy and infusion services intended for patients with complex chronic conditions.

Wellsheet / Elsevier: The company was acquired by Elsevier, for an undisclosed amount on June 3, 2026. The company is a developer of a cloud-based electronic health record software designed to prioritize clinical content within physician workflow.